T-cell lymphoma


Also found in: Dictionary, Thesaurus, Encyclopedia, Wikipedia.

T-cell lymphoma

A malignant proliferation of T cells arising in the skin, diagnosed by detecting rearrangement of the T-cell receptor's β chain; TCLs are often 'driven' by EBV and other viral infections; 90% of all Pts with TCL have extracutaneous involvement when diagnosed. See Mycosis fungoides.
T-cell lymphomas
Small lymphocytic (well-differentiated lymphocyte-like) lymphoma–13%
Convoluted cell lymphoma or poorly-differentiated lymphocytic lymphoma–52%
Immunoblastic sarcoma or 'histiocytic' lymphoma–19%
Mycosis fungoides/Sézary syndrome–11%
Lymphoepithelial cell (Lennert's) lymphoma–5%
Cutaneous T-cell lymphoma
HTLV (I, II)–induced lymphoma

T-cell lymphoma

See MYCOSIS FUNGOIDES.
References in periodicals archive ?
T-cell lymphoma is instrumental in making the correct diagnosis.
Peripheral T-cell lymphoma (PTCL) is a type of non-Hodgkin lymphoma and classified as intermediate-grade.
Suh, "Cutaneous T-cell lymphoma in asians," ISRN Dermatology, vol.
Type II enteropathy-associated T-cell lymphoma is a subset of EATL which does not appear to be associated with celiac disease and therefore has a broader geographic distribution.
Coverage of the Cutaneous T-Cell Lymphoma pipeline on the basis of route of administration and molecule type.
The 200 cases of non-Hodgkin's lymphoma included 118 T-cell lymphomas, 30 B-cell lymphomas, and 52 indeterminate types.
Cutaneous T-cell lymphoma, like all cancers, is a terrible burden on families worldwide.
Many aggressive B-cell NHL seen in HIV patients, especially those with plasmacytic differentiation, often lack CD20 and exhibit aberrant T-cell antigen expression [72], These lymphomas may falsely lead to an impression of T-cell lymphoma, and could thereby skew the published data reported.
T-CELL lymphoma is a rare type of cancer that affects the immune system.
Hence, although T-cell clonality analysis by PCR and capillary electrophoresis (CE) has been used extensively in lymphoproliferative disorders in general, there are very few reports describing their application to the differential diagnosis of cutaneous T-cell lymphoma (1, 2) or to cases of cutaneous lymphoproliferative disorders with less conclusive histology, where their superior resolution properties have provided strong confirmatory evidence of evolving lymphoma development (3).
The therapeutic cytokine produced significant improvement in nearly 50% of cutaneous T-cell lymphoma (CTCL) patients treated in recent phase I and phase II clinical trials, Dr.
Ligand Pharmaceuticals Incorporated (Nasdaq: LGND), San Diego, has submitted a regulatory application to market its anti-cancer medicine ONZAR(TM) (denileukin diftitox) in the European Union for the treatment of cutaneous T-cell lymphoma (CTCL) patients.